Stock Analysis on Net

AbbVie Inc. (NYSE:ABBV)

Análisis de ratios de rentabilidad
Datos trimestrales

Bajo nivel de dificultad

Índices de rentabilidad (resumen)

AbbVie Inc., ratios de rentabilidad (datos trimestrales)

Microsoft Excel LibreOffice Calc
30 jun. 2020 31 mar. 2020 31 dic. 2019 30 sept. 2019 30 jun. 2019 31 mar. 2019 31 dic. 2018 30 sept. 2018 30 jun. 2018 31 mar. 2018 31 dic. 2017 30 sept. 2017 30 jun. 2017 31 mar. 2017 31 dic. 2016 30 sept. 2016 30 jun. 2016 31 mar. 2016 31 dic. 2015 30 sept. 2015 30 jun. 2015 31 mar. 2015
Ratios de ventas
Ratio de margen de beneficio bruto 73.56% 77.43% 77.64% 77.32% 77.41% 77.07% 76.44% 75.22% 74.93% 75.18% 75.05% 76.85% 76.78% 76.81% 77.25% 77.21% 78.12% 79.28% 80.31%
Ratio de margen de beneficio operativo 30.17% 39.86% 39.03% 20.04% 21.85% 19.88% 19.49% 32.99% 32.84% 34.03% 33.99% 37.24% 36.74% 36.33% 36.60% 36.21% 35.00% 34.18% 32.97%
Ratio de margen de beneficio neto 19.20% 24.77% 23.69% 9.90% 12.62% 16.42% 17.36% 23.50% 20.84% 21.55% 18.82% 24.38% 24.77% 24.07% 23.22% 24.08% 23.11% 23.03% 22.50%
Ratios de inversión
Retorno sobre el capital contable (ROE) 47.30% 179.59% 104.16% 99.42% 110.08% 126.25% 128.41% 93.97% 101.42% 117.94% 130.39%
Ratio de retorno sobre activos (ROA) 4.65% 9.25% 8.84% 5.48% 7.21% 9.44% 9.58% 11.43% 10.46% 9.20% 7.50% 9.66% 9.87% 9.61% 9.01% 9.12% 8.51% 10.19% 9.70%

Fuente: AbbVie Inc. (NYSE:ABBV) | Analysis of profitability ratios (Q) (www.stock-analysis-on.net)

Coeficiente de rentabilidad Descripción La compañia
Ratio de margen de beneficio bruto El índice de margen de beneficio bruto indica el porcentaje de ingresos disponibles para cubrir gastos operativos y otros gastos. El índice de margen de beneficio bruto de AbbVie Inc. se deterioró del cuarto trimestre de 2019 al primer trimestre de 2020 y del primer trimestre de 2020 al segundo trimestre de 2020.
Ratio de margen de beneficio operativo Un índice de rentabilidad calculado como el ingreso operativo dividido por los ingresos. La relación de margen de beneficio operativo de AbbVie Inc. mejoró del cuarto trimestre de 2019 al primer trimestre de 2020, pero luego se deterioró significativamente del primer trimestre de 2020 al segundo trimestre de 2020.
Ratio de margen de beneficio neto Un indicador de rentabilidad, calculado como el ingreso neto dividido por los ingresos. El índice de margen de beneficio neto de AbbVie Inc. mejoró del cuarto trimestre de 2019 al primer trimestre de 2020, pero luego se deterioró significativamente del primer trimestre de 2020 al segundo trimestre de 2020.

Coeficiente de rentabilidad Descripción La compañia
ROE Un índice de rentabilidad calculado como el ingreso neto dividido por el patrimonio neto.
ROA Un índice de rentabilidad calculado como el ingreso neto dividido entre los activos totales. El ROA de AbbVie Inc. mejoró del cuarto trimestre de 2019 al primer trimestre de 2020, pero luego se deterioró significativamente del primer trimestre de 2020 al segundo trimestre de 2020.

Ratio de margen de beneficio bruto

AbbVie Inc., margen de beneficio bruto, cálculo (datos trimestrales)

Microsoft Excel LibreOffice Calc
30 jun. 2020 31 mar. 2020 31 dic. 2019 30 sept. 2019 30 jun. 2019 31 mar. 2019 31 dic. 2018 30 sept. 2018 30 jun. 2018 31 mar. 2018 31 dic. 2017 30 sept. 2017 30 jun. 2017 31 mar. 2017 31 dic. 2016 30 sept. 2016 30 jun. 2016 31 mar. 2016 31 dic. 2015 30 sept. 2015 30 jun. 2015 31 mar. 2015
Datos financieros seleccionados (US $ en millones)
Margen bruto 6,714  6,677  6,698  6,559  6,436  6,134  6,283  6,401  6,344  6,007  5,459  5,379  5,416  4,922  5,241  4,928  5,047  4,589  4,925  4,777  4,559  4,098 
Los ingresos netos 10,425  8,619  8,704  8,479  8,255  7,828  8,305  8,236  8,278  7,934  7,739  6,995  6,944  6,538  6,796  6,432  6,452  5,958  6,400  5,944  5,475  5,040 
Coeficiente de rentabilidad
Ratio de margen de beneficio bruto1 73.56% 77.43% 77.64% 77.32% 77.41% 77.07% 76.44% 75.22% 74.93% 75.18% 75.05% 76.85% 76.78% 76.81% 77.25% 77.21% 78.12% 79.28% 80.31%
Puntos de referencia
Ratio de margen de beneficio bruto, competidores2
Abbott Laboratories 50.97% 52.13% 52.46% 52.39% 52.17% 51.57% 51.32% 50.57% 50.38% 49.39% 47.75% 48.59% 49.21% 51.32% 54.09% 54.17% 53.99% 53.93% 54.19%
Amgen Inc. 77.15% 78.90% 80.38% 81.19% 81.23% 81.26% 81.80% 81.61% 81.78% 81.69% 81.33% 81.37% 81.26% 81.05% 80.99% 80.68% 80.64% 80.23% 79.82%
Biogen Inc. 87.97% 87.47% 86.40% 85.97% 85.59% 85.72% 86.50% 86.12% 86.43% 86.57% 86.72% 87.34% 86.80% 86.56% 87.08% 87.46% 88.21% 88.65% 88.48%
Bristol-Myers Squibb Co. 69.59% 68.08% 69.10% 69.65% 69.93% 70.77% 70.98% 70.37% 70.12% 69.62% 70.80% 71.92% 72.78% 74.19% 74.54% 75.56% 75.55% 75.67% 76.39%
Eli Lilly & Co. 78.67% 79.22% 78.85% 77.78% 76.67% 74.96% 73.81% 73.39% 72.92% 72.95% 73.46% 73.69% 73.89% 73.78% 73.35% 73.23% 73.72% 74.39% 74.76%
Gilead Sciences Inc. 78.25% 79.06% 78.86% 79.27% 78.98% 78.02% 77.61% 79.21% 80.31% 81.82% 82.97% 84.51% 84.71% 85.95% 85.77% 86.36% 86.91% 86.69% 87.54%
Illumina Inc. 70.34% 70.36% 69.63% 69.24% 68.84% 69.06% 69.01% 69.44% 68.85% 67.98% 66.35% 65.68% 66.26% 67.53% 69.48% 69.91% 69.96% 69.74% 69.80%
Johnson & Johnson 65.66% 66.15% 66.42% 66.49% 66.67% 66.80% 66.79% 66.36% 65.69% 66.22% 66.84% 68.20% 69.35% 69.88% 69.84% 69.52% 69.58% 69.25% 69.27%
Merck & Co. Inc. 70.06% 70.11% 69.87% 70.13% 69.89% 68.94% 68.06% 67.35% 67.81% 68.22% 68.16% 68.09% 67.92% 66.61% 65.10% 63.89% 62.58% 62.07% 62.19%
Pfizer Inc. 79.94% 79.94% 80.25% 79.85% 79.91% 79.36% 79.03% 78.58% 78.24% 78.48% 78.61% 78.66% 78.15% 77.28% 76.66% 76.48% 77.71% 79.09% 80.25%
Regeneron Pharmaceuticals Inc. 88.21% 89.72% 90.05% 91.14% 92.27% 92.79% 93.53% 93.36% 93.28% 92.95% 93.24% 93.37% 94.16% 94.53% 93.83% 92.90% 91.38% 90.52% 90.43%
Vertex Pharmaceuticals Inc. 87.71% 87.24% 86.84% 86.60% 86.56% 86.74% 86.56% 86.88% 87.31% 87.59% 88.95% 89.04% 89.08% 89.76% 87.64% 87.16% 87.72% 87.39% 87.94%
Zoetis Inc. 69.73% 69.51% 68.18% 67.38% 66.92% 66.49% 67.19% 68.12% 68.04% 67.31% 66.55% 65.14% 64.91% 65.30% 65.92% 65.32% 64.90% 64.08% 63.53%

Fuente: AbbVie Inc. (NYSE:ABBV) | Analysis of profitability ratios (Q) (www.stock-analysis-on.net)

1 Q2 2020 cálculo
Ratio de margen de beneficio bruto = 100 × (Margen brutoQ2 2020 + Margen brutoQ1 2020 + Margen brutoQ4 2019 + Margen brutoQ3 2019) ÷ (Los ingresos netosQ2 2020 + Los ingresos netosQ1 2020 + Los ingresos netosQ4 2019 + Los ingresos netosQ3 2019)
= 100 × (6,714 + 6,677 + 6,698 + 6,559) ÷ (10,425 + 8,619 + 8,704 + 8,479) = 73.56%

2 Haga clic en el nombre del competidor para ver los cálculos.

Coeficiente de rentabilidad Descripción La compañia
Ratio de margen de beneficio bruto El índice de margen de beneficio bruto indica el porcentaje de ingresos disponibles para cubrir gastos operativos y otros gastos. El índice de margen de beneficio bruto de AbbVie Inc. se deterioró del cuarto trimestre de 2019 al primer trimestre de 2020 y del primer trimestre de 2020 al segundo trimestre de 2020.

Ratio de margen de beneficio operativo

AbbVie Inc., ratio de margen de beneficio operativo, cálculo (datos trimestrales)

Microsoft Excel LibreOffice Calc
30 jun. 2020 31 mar. 2020 31 dic. 2019 30 sept. 2019 30 jun. 2019 31 mar. 2019 31 dic. 2018 30 sept. 2018 30 jun. 2018 31 mar. 2018 31 dic. 2017 30 sept. 2017 30 jun. 2017 31 mar. 2017 31 dic. 2016 30 sept. 2016 30 jun. 2016 31 mar. 2016 31 dic. 2015 30 sept. 2015 30 jun. 2015 31 mar. 2015
Datos financieros seleccionados (US $ en millones)
Ganancias operativas 752  3,603  3,956  2,617  3,400  3,010  (2,441) 3,159  2,762  2,903  1,794  2,705  2,674  2,419  2,358  2,361  2,387  2,278  2,113  1,885  1,852  1,687 
Los ingresos netos 10,425  8,619  8,704  8,479  8,255  7,828  8,305  8,236  8,278  7,934  7,739  6,995  6,944  6,538  6,796  6,432  6,452  5,958  6,400  5,944  5,475  5,040 
Coeficiente de rentabilidad
Ratio de margen de beneficio operativo1 30.17% 39.86% 39.03% 20.04% 21.85% 19.88% 19.49% 32.99% 32.84% 34.03% 33.99% 37.24% 36.74% 36.33% 36.60% 36.21% 35.00% 34.18% 32.97%
Puntos de referencia
Ratio de margen de beneficio operativo, competidores2
Abbott Laboratories 12.78% 14.18% 14.21% 13.74% 13.27% 12.31% 11.94% 10.45% 10.11% 8.92% 6.30% 7.89% 8.77% 11.03% 15.27% 14.74% 13.95% 13.64% 14.05%
Amgen Inc. 39.76% 41.89% 43.57% 44.83% 44.05% 44.53% 45.55% 45.82% 46.46% 46.07% 45.76% 46.66% 46.93% 45.68% 44.74% 43.33% 42.46% 41.53% 40.44%
Biogen Inc. 50.93% 51.03% 48.98% 47.13% 46.90% 42.40% 43.77% 44.67% 45.58% 46.49% 43.54% 40.25% 38.72% 41.59% 44.99% 47.59% 47.86% 47.11% 45.44%
Bristol-Myers Squibb Co. 11.67% 16.30% 22.62% 28.64% 28.60% 23.44% 22.69% 18.64% 15.93% 17.50% 17.39% 19.71% 21.73% 24.06% 23.83% 19.21% 16.34% 11.09% 11.41%
Eli Lilly & Co. 24.48% 25.64% 22.29% 20.00% 19.48% 12.50% 15.15% 12.34% 9.11% 14.88% 9.38% 12.43% 14.23% 12.92% 16.30% 14.31% 14.56% 14.27% 13.47%
Gilead Sciences Inc. -4.40% 19.89% 19.38% 19.71% 38.44% 37.87% 37.83% 42.81% 46.25% 51.51% 55.04% 58.72% 58.71% 58.46% 58.87% 61.67% 63.83% 66.22% 69.03%
Illumina Inc. 25.69% 27.28% 27.80% 26.42% 24.88% 25.58% 26.49% 28.25% 27.58% 26.29% 22.02% 20.01% 20.06% 21.35% 24.48% 24.80% 24.55% 24.77% 27.61%
Johnson & Johnson 24.64% 25.62% 24.15% 24.15% 22.63% 22.69% 24.27% 22.59% 23.05% 23.63% 24.07% 27.02% 28.55% 28.83% 28.72% 26.37% 25.66% 25.00% 25.05%
Merck & Co. Inc. 25.40% 25.49% 24.77% 25.56% 26.73% 24.38% 19.62% 17.84% 12.28% 13.57% 16.28% 9.92% 16.85% 14.45% 13.51% 19.60% 18.10% 18.19% 17.54%
Pfizer Inc. 23.75% 25.38% 25.46% 26.30% 27.50% 26.86% 26.10% 26.18% 26.00% 25.86% 25.92% 24.69% 23.57% 22.94% 22.73% 22.96% 24.02% 24.86% 24.20%
Regeneron Pharmaceuticals Inc. 34.64% 30.45% 28.10% 29.55% 29.58% 35.41% 37.77% 37.00% 36.89% 36.54% 35.41% 34.22% 32.29% 28.76% 27.38% 25.67% 26.77% 29.26% 30.51%
Vertex Pharmaceuticals Inc. 38.67% 34.05% 28.77% 21.38% 25.48% 23.98% 20.84% 22.38% 3.87% -0.77% 4.95% 1.62% 16.16% 14.62% 0.58% -5.02% -8.65% -23.94% -45.23%
Zoetis Inc. 33.36% 32.72% 31.42% 31.01% 29.80% 30.05% 31.12% 33.00% 33.86% 33.02% 32.15% 29.43% 28.34% 28.55% 28.48% 26.22% 24.91% 17.35% 15.74%

Fuente: AbbVie Inc. (NYSE:ABBV) | Analysis of profitability ratios (Q) (www.stock-analysis-on.net)

1 Q2 2020 cálculo
Ratio de margen de beneficio operativo = 100 × (Ganancias operativasQ2 2020 + Ganancias operativasQ1 2020 + Ganancias operativasQ4 2019 + Ganancias operativasQ3 2019) ÷ (Los ingresos netosQ2 2020 + Los ingresos netosQ1 2020 + Los ingresos netosQ4 2019 + Los ingresos netosQ3 2019)
= 100 × (752 + 3,603 + 3,956 + 2,617) ÷ (10,425 + 8,619 + 8,704 + 8,479) = 30.17%

2 Haga clic en el nombre del competidor para ver los cálculos.

Coeficiente de rentabilidad Descripción La compañia
Ratio de margen de beneficio operativo Un índice de rentabilidad calculado como el ingreso operativo dividido por los ingresos. El índice de margen de beneficio operativo de AbbVie Inc. mejoró del cuarto trimestre de 2019 al primer trimestre de 2020, pero luego se deterioró significativamente del primer trimestre de 2020 al segundo trimestre de 2020.

Ratio de margen de beneficio neto

AbbVie Inc., margen de beneficio neto, cálculo (datos trimestrales)

Microsoft Excel LibreOffice Calc
30 jun. 2020 31 mar. 2020 31 dic. 2019 30 sept. 2019 30 jun. 2019 31 mar. 2019 31 dic. 2018 30 sept. 2018 30 jun. 2018 31 mar. 2018 31 dic. 2017 30 sept. 2017 30 jun. 2017 31 mar. 2017 31 dic. 2016 30 sept. 2016 30 jun. 2016 31 mar. 2016 31 dic. 2015 30 sept. 2015 30 jun. 2015 31 mar. 2015
Datos financieros seleccionados (US $ en millones)
Ganancias (pérdidas) netas atribuibles a AbbVie Inc. (738) 3,010  2,801  1,884  741  2,456  (1,826) 2,747  1,983  2,783  52  1,631  1,915  1,711  1,391  1,598  1,610  1,354  1,517  1,239  1,366  1,022 
Los ingresos netos 10,425  8,619  8,704  8,479  8,255  7,828  8,305  8,236  8,278  7,934  7,739  6,995  6,944  6,538  6,796  6,432  6,452  5,958  6,400  5,944  5,475  5,040 
Coeficiente de rentabilidad
Ratio de margen de beneficio neto1 19.20% 24.77% 23.69% 9.90% 12.62% 16.42% 17.36% 23.50% 20.84% 21.55% 18.82% 24.38% 24.77% 24.07% 23.22% 24.08% 23.11% 23.03% 22.50%
Puntos de referencia
Ratio de margen de beneficio neto, competidores2
Abbott Laboratories 9.89% 11.15% 11.56% 10.50% 9.36% 8.53% 7.74% 2.91% 3.13% 1.67% 1.74% 8.37% 4.96% 6.74% 6.71% 6.61% 11.08% 12.00% 21.68%
Amgen Inc. 31.53% 33.64% 35.32% 36.14% 35.57% 35.93% 37.25% 9.96% 10.72% 10.11% 9.08% 37.36% 37.24% 36.12% 35.27% 35.19% 34.48% 33.86% 33.13%
Biogen Inc. 40.91% 40.76% 40.96% 37.91% 37.62% 33.79% 32.93% 24.08% 23.06% 23.54% 20.69% 29.44% 28.10% 30.17% 32.34% 34.03% 33.97% 33.79% 32.95%
Bristol-Myers Squibb Co. -1.61% 3.08% 13.15% 23.39% 26.00% 22.09% 21.81% 6.50% 1.74% 4.37% 4.85% 20.56% 22.66% 24.22% 22.94% 18.22% 16.29% 9.31% 9.45%
Eli Lilly & Co. 24.48% 23.97% 37.27% 35.10% 33.76% 26.12% 13.16% 1.85% -0.60% 4.82% -0.89% 9.90% 11.12% 10.13% 12.90% 11.73% 11.97% 11.49% 12.07%
Gilead Sciences Inc. -1.18% 22.17% 24.35% 12.24% 27.14% 26.93% 25.16% 7.27% 9.69% 14.26% 18.03% 42.90% 43.55% 44.11% 45.07% 48.40% 51.16% 53.48% 56.32%
Illumina Inc. 20.68% 26.49% 28.28% 28.13% 27.55% 25.05% 24.78% 21.09% 20.88% 19.31% 26.38% 30.14% 30.07% 30.52% 19.29% 18.70% 18.70% 18.40% 20.79%
Johnson & Johnson 18.86% 20.75% 18.42% 17.32% 20.08% 17.99% 18.75% 1.89% 1.70% 1.58% 1.70% 21.28% 22.52% 22.87% 23.01% 22.27% 21.20% 22.15% 21.99%
Merck & Co. Inc. 22.20% 21.10% 21.01% 20.26% 21.10% 19.50% 14.71% 8.02% 3.25% 3.88% 5.97% 7.15% 12.71% 10.88% 9.85% 13.76% 13.01% 11.72% 11.25%
Pfizer Inc. 28.80% 31.17% 31.45% 30.57% 23.58% 21.31% 20.79% 44.63% 42.35% 41.29% 40.55% 18.69% 15.90% 13.88% 13.66% 11.77% 13.47% 14.95% 14.25%
Regeneron Pharmaceuticals Inc. 37.30% 28.56% 26.91% 28.13% 28.59% 35.12% 36.42% 28.24% 25.65% 23.54% 20.41% 23.17% 22.05% 19.34% 18.42% 16.85% 15.98% 16.72% 15.50%
Vertex Pharmaceuticals Inc. 38.51% 31.35% 28.27% 59.23% 64.13% 66.01% 68.80% 22.87% 15.84% 9.36% 10.59% 8.53% 12.19% 8.78% -6.58% -13.17% -17.66% -30.91% -53.89%
Zoetis Inc. 25.50% 25.41% 23.96% 23.76% 22.74% 23.47% 24.52% 20.35% 19.95% 17.97% 16.28% 18.29% 17.50% 17.25% 16.80% 14.10% 13.15% 7.83% 7.11%

Fuente: AbbVie Inc. (NYSE:ABBV) | Analysis of profitability ratios (Q) (www.stock-analysis-on.net)

1 Q2 2020 cálculo
Ratio de margen de beneficio neto = 100 × (Ganancias (pérdidas) netas atribuibles a AbbVie Inc.Q2 2020 + Ganancias (pérdidas) netas atribuibles a AbbVie Inc.Q1 2020 + Ganancias (pérdidas) netas atribuibles a AbbVie Inc.Q4 2019 + Ganancias (pérdidas) netas atribuibles a AbbVie Inc.Q3 2019) ÷ (Los ingresos netosQ2 2020 + Los ingresos netosQ1 2020 + Los ingresos netosQ4 2019 + Los ingresos netosQ3 2019)
= 100 × (-738 + 3,010 + 2,801 + 1,884) ÷ (10,425 + 8,619 + 8,704 + 8,479) = 19.20%

2 Haga clic en el nombre del competidor para ver los cálculos.

Coeficiente de rentabilidad Descripción La compañia
Ratio de margen de beneficio neto Un indicador de rentabilidad, calculado como el ingreso neto dividido por los ingresos. La relación de margen de beneficio neto de AbbVie Inc. mejoró del cuarto trimestre de 2019 al primer trimestre de 2020, pero luego se deterioró significativamente del primer trimestre de 2020 al segundo trimestre de 2020.

Retorno sobre el capital contable (ROE)

AbbVie Inc., ROE, cálculo (datos trimestrales)

Microsoft Excel LibreOffice Calc
30 jun. 2020 31 mar. 2020 31 dic. 2019 30 sept. 2019 30 jun. 2019 31 mar. 2019 31 dic. 2018 30 sept. 2018 30 jun. 2018 31 mar. 2018 31 dic. 2017 30 sept. 2017 30 jun. 2017 31 mar. 2017 31 dic. 2016 30 sept. 2016 30 jun. 2016 31 mar. 2016 31 dic. 2015 30 sept. 2015 30 jun. 2015 31 mar. 2015
Datos financieros seleccionados (US $ en millones)
Ganancias (pérdidas) netas atribuibles a AbbVie Inc. (738) 3,010  2,801  1,884  741  2,456  (1,826) 2,747  1,983  2,783  52  1,631  1,915  1,711  1,391  1,598  1,610  1,354  1,517  1,239  1,366  1,022 
Capital contable (déficit) 14,708  (7,415) (8,172) (8,226) (8,566) (7,826) (8,446) (2,921) (3,375) 3,553  5,097  6,687  6,009  4,998  4,636  6,469  5,640  4,643  3,945  4,863  5,504  1,377 
Coeficiente de rentabilidad
ROE1 47.30% 179.59% 104.16% 99.42% 110.08% 126.25% 128.41% 93.97% 101.42% 117.94% 130.39%
Puntos de referencia
ROE, competidores2
Abbott Laboratories 10.17% 11.84% 11.86% 10.35% 9.14% 8.48% 7.76% 2.89% 3.03% 1.52% 1.54% 6.57% 3.71% 4.79% 6.82% 6.59% 11.02% 11.81% 20.85%
Amgen Inc. 68.48% 80.92% 81.07% 73.83% 73.73% 74.55% 67.15% 15.35% 15.86% 14.21% 7.84% 25.37% 25.77% 25.76% 25.85% 24.65% 24.67% 25.16% 24.71%
Biogen Inc. 52.41% 46.85% 44.13% 38.55% 40.87% 33.74% 33.98% 23.15% 24.21% 21.09% 20.13% 27.10% 28.42% 30.31% 30.50% 32.06% 33.48% 35.78% 37.84%
Bristol-Myers Squibb Co. -1.15% 1.91% 6.66% 32.04% 38.65% 33.80% 35.07% 10.50% 3.05% 7.18% 8.58% 28.61% 31.20% 33.55% 27.55% 21.56% 19.24% 10.94% 10.97%
Eli Lilly & Co. 137.26% 179.72% 319.09% 234.97% 282.08% 252.24% 32.88% 3.44% -1.24% 7.74% -1.76% 14.94% 17.35% 15.58% 19.54% 15.68% 16.85% 15.45% 16.53%
Gilead Sciences Inc. -1.43% 22.49% 23.91% 13.07% 26.33% 26.84% 25.51% 6.94% 10.19% 16.82% 22.64% 46.69% 53.86% 61.82% 71.48% 89.38% 105.21% 129.43% 97.70%
Illumina Inc. 15.19% 20.32% 21.72% 21.92% 21.65% 21.36% 21.98% 19.53% 19.90% 18.85% 26.41% 27.38% 27.54% 29.01% 21.06% 19.79% 21.05% 20.82% 24.97%
Johnson & Johnson 24.11% 28.01% 25.42% 24.31% 26.87% 24.90% 25.60% 2.39% 2.18% 1.97% 2.16% 21.39% 22.71% 23.46% 23.49% 21.91% 20.73% 21.40% 21.66%
Merck & Co. Inc. 37.91% 38.72% 37.99% 34.70% 33.88% 30.50% 23.30% 10.32% 4.12% 4.69% 6.97% 7.44% 12.89% 10.91% 9.78% 12.55% 11.84% 10.53% 9.94%
Pfizer Inc. 22.02% 24.28% 25.77% 24.91% 21.24% 19.52% 17.59% 33.40% 32.31% 29.72% 29.88% 16.14% 14.26% 12.49% 12.12% 9.90% 11.22% 12.09% 10.75%
Regeneron Pharmaceuticals Inc. 32.94% 18.79% 19.08% 20.41% 21.21% 25.70% 27.91% 22.85% 22.14% 21.74% 19.51% 21.12% 20.91% 19.79% 20.13% 17.75% 18.23% 19.69% 17.40%
Vertex Pharmaceuticals Inc. 27.67% 23.38% 19.34% 40.81% 43.70% 45.63% 47.28% 22.27% 15.46% 9.41% 12.99% 10.93% 15.55% 11.82% -9.69% -21.41% -28.03% -41.73% -59.19%
Zoetis Inc. 54.23% 58.52% 55.39% 54.56% 57.03% 59.91% 65.35% 54.96% 56.60% 49.90% 48.81% 47.11% 51.20% 53.14% 55.21% 43.47% 47.09% 32.45% 31.74%

Fuente: AbbVie Inc. (NYSE:ABBV) | Analysis of profitability ratios (Q) (www.stock-analysis-on.net)

1 Q2 2020 cálculo
ROE = 100 × (Ganancias (pérdidas) netas atribuibles a AbbVie Inc.Q2 2020 + Ganancias (pérdidas) netas atribuibles a AbbVie Inc.Q1 2020 + Ganancias (pérdidas) netas atribuibles a AbbVie Inc.Q4 2019 + Ganancias (pérdidas) netas atribuibles a AbbVie Inc.Q3 2019) ÷ Capital contable (déficit)
= 100 × (-738 + 3,010 + 2,801 + 1,884) ÷ 14,708 = 47.30%

2 Haga clic en el nombre del competidor para ver los cálculos.

Coeficiente de rentabilidad Descripción La compañia
ROE Un índice de rentabilidad calculado como el ingreso neto dividido por el patrimonio neto.

Ratio de retorno sobre activos (ROA)

AbbVie Inc., ROA, cálculo (datos trimestrales)

Microsoft Excel LibreOffice Calc
30 jun. 2020 31 mar. 2020 31 dic. 2019 30 sept. 2019 30 jun. 2019 31 mar. 2019 31 dic. 2018 30 sept. 2018 30 jun. 2018 31 mar. 2018 31 dic. 2017 30 sept. 2017 30 jun. 2017 31 mar. 2017 31 dic. 2016 30 sept. 2016 30 jun. 2016 31 mar. 2016 31 dic. 2015 30 sept. 2015 30 jun. 2015 31 mar. 2015
Datos financieros seleccionados (US $ en millones)
Ganancias (pérdidas) netas atribuibles a AbbVie Inc. (738) 3,010  2,801  1,884  741  2,456  (1,826) 2,747  1,983  2,783  52  1,631  1,915  1,711  1,391  1,598  1,610  1,354  1,517  1,239  1,366  1,022 
Los activos totales 149,530  91,199  89,115  59,441  57,142  56,769  59,352  66,164  61,641  69,342  70,786  68,840  66,994  65,664  66,099  66,626  67,211  53,720  53,050  54,832  53,855  26,699 
Coeficiente de rentabilidad
ROA1 4.65% 9.25% 8.84% 5.48% 7.21% 9.44% 9.58% 11.43% 10.46% 9.20% 7.50% 9.66% 9.87% 9.61% 9.01% 9.12% 8.51% 10.19% 9.70%
Puntos de referencia
ROA, competidores2
Abbott Laboratories 4.52% 5.36% 5.43% 4.80% 4.23% 3.88% 3.53% 1.24% 1.35% 0.67% 0.63% 2.91% 1.65% 2.12% 2.66% 3.47% 5.72% 6.17% 10.72%
Amgen Inc. 11.23% 12.45% 13.13% 13.55% 13.40% 12.62% 12.64% 3.27% 3.49% 3.12% 2.48% 10.18% 10.27% 10.14% 9.95% 9.71% 9.85% 9.61% 9.69%
Biogen Inc. 23.23% 22.51% 21.62% 19.63% 20.14% 17.65% 17.52% 12.50% 12.39% 11.36% 10.73% 15.11% 15.13% 16.42% 16.19% 17.58% 17.75% 17.87% 18.19%
Bristol-Myers Squibb Co. -0.44% 0.74% 2.65% 9.85% 11.24% 14.77% 14.06% 4.24% 1.15% 2.78% 3.00% 12.45% 13.73% 14.68% 13.22% 9.98% 8.74% 4.94% 4.93%
Eli Lilly & Co. 13.39% 13.46% 21.17% 20.97% 20.28% 16.46% 7.36% 1.01% -0.34% 2.53% -0.45% 5.17% 5.98% 5.81% 7.05% 6.50% 6.76% 6.68% 6.77%
Gilead Sciences Inc. -0.46% 8.31% 8.74% 4.55% 9.42% 9.38% 8.57% 2.47% 3.38% 5.30% 6.58% 17.94% 20.27% 21.90% 23.70% 26.63% 32.71% 36.30% 34.93%
Illumina Inc. 9.56% 12.97% 13.70% 13.73% 13.45% 11.52% 11.87% 10.12% 11.08% 10.23% 13.81% 15.49% 15.39% 16.10% 10.81% 10.49% 10.86% 10.93% 12.52%
Johnson & Johnson 9.59% 11.07% 9.59% 9.10% 10.53% 9.78% 10.00% 0.99% 0.88% 0.79% 0.83% 10.17% 10.69% 11.39% 11.71% 11.36% 10.75% 11.41% 11.55%
Merck & Co. Inc. 11.56% 11.95% 11.66% 11.18% 11.15% 10.20% 7.53% 3.93% 1.58% 1.84% 2.72% 3.11% 5.48% 4.50% 4.11% 5.58% 5.32% 4.67% 4.36%
Pfizer Inc. 7.96% 9.49% 9.72% 9.51% 8.10% 7.38% 7.00% 14.19% 13.67% 13.21% 12.40% 5.70% 4.94% 4.32% 4.20% 3.51% 4.13% 4.68% 4.16%
Regeneron Pharmaceuticals Inc. 20.68% 14.46% 14.29% 15.38% 15.71% 18.88% 20.83% 16.64% 15.99% 15.23% 13.67% 14.69% 14.24% 12.32% 12.84% 11.68% 11.97% 12.56% 11.34%
Vertex Pharmaceuticals Inc. 20.37% 16.99% 14.15% 28.53% 31.50% 32.94% 33.57% 14.00% 9.58% 5.72% 7.43% 6.12% 7.91% 6.02% -3.87% -8.38% -10.79% -16.05% -22.26%
Zoetis Inc. 12.37% 13.97% 12.99% 12.96% 12.52% 12.75% 13.25% 11.13% 12.96% 11.25% 10.06% 10.09% 11.25% 11.18% 10.73% 8.93% 8.50% 5.07% 4.28%

Fuente: AbbVie Inc. (NYSE:ABBV) | Analysis of profitability ratios (Q) (www.stock-analysis-on.net)

1 Q2 2020 cálculo
ROA = 100 × (Ganancias (pérdidas) netas atribuibles a AbbVie Inc.Q2 2020 + Ganancias (pérdidas) netas atribuibles a AbbVie Inc.Q1 2020 + Ganancias (pérdidas) netas atribuibles a AbbVie Inc.Q4 2019 + Ganancias (pérdidas) netas atribuibles a AbbVie Inc.Q3 2019) ÷ Los activos totales
= 100 × (-738 + 3,010 + 2,801 + 1,884) ÷ 149,530 = 4.65%

2 Haga clic en el nombre del competidor para ver los cálculos.

Coeficiente de rentabilidad Descripción La compañia
ROA Un índice de rentabilidad calculado como el ingreso neto dividido entre los activos totales. El ROA de AbbVie Inc. mejoró del cuarto trimestre de 2019 al primer trimestre de 2020, pero luego se deterioró significativamente del primer trimestre de 2020 al segundo trimestre de 2020.